CLINICAL IMMUNOLOGY
Lupus nephritis in children – 10 years’ experience
More details
Hide details
Submission date: 2016-05-10
Final revision date: 2016-06-02
Acceptance date: 2016-06-14
Publication date: 2016-10-25
Cent Eur J Immunol 2016;41(3):248-254
KEYWORDS
ABSTRACT
Systemic lupus erythematosus (SLE) in children is usually more severe than it is in adults and there is a higher incidence of renal involvement. We described 18 children (16 girls, 2 boys) with lupus nephritis (LN), whose average age was 14.4 ±1.81 years. Disease activity was assessed according to SLEDAI (SLE Disease Activity Index). Renal biopsy was classified according to the INS/RPS (International Society of Nephrology/Renal Pathology Society). The patients were treated with steroids (100%) and pulses of cyclophosphamide (88.9%) or mycophenolate mofetil (11.1%), next azathioprine or mycophenolate mofetil with prednisone in reduced doses. In children with renal/multi-organ insufficiency and/or septicaemia, renal replacement therapy (27.8%), and plasmapheresis (22.2%) were used in the initial treatment. The SLEDAI initial activity was high in 44.4% and moderate in 55.6% of children. LN manifested as: nephrotic syndrome (83.3%), microhaematuria (100%), leukocyturia (60%), hypertension (72.2%), and acute renal injury (83.3%); mean GFR was 54.55 ±33.09 ml/min/1.73 m2. In the renal biopsy, class IV LN according to INS/RPS was mainly diagnosed (82%). At the end of follow-up, mean observation time 32.1±23.36 months: mean GFR was 90.87 ±12.13 ml/min/1.73 m2, proteinuria disappeared in 66.7% and decreased in 33.3% of children to the average of 1.7 g/day (range: 0.5-4.0 g/day), hypertension was observed in 83.4% of children. Intensive immunosuppressive treatment with pulses of cyclophosphamide in early stage of LN in children is very effective.
REFERENCES (39)
1.
Schwartz N, Goilav B (2014): The pathogenesis, diagnosis and treatment of lupus nephritis. Curr Opin Rheumatol 26: 502-509.
2.
Lech M, Anders HJ (2013): The pathogenesis of lupus nephritis. J Am Soc Nephrol 24: 1357-1366.
3.
Hahn BH, McMahon MA, Wilkinson A, et al. (2012): American College of Rheumatology guidelines for screening, case definition, treatment, and management of lupus nephritis. Arthritis Care Res 64: 797-808.
4.
Isenberg D, Appel GB, Contreras G, et al. (2010): Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study. Rheumatology 49: 128-140.
5.
Malattia C, Martini A (2013): Paediatric-onset systemic lupus erythematosus. Best Pract Res Clin Rheumatol 27: 351-362.
6.
Mina R, Brunner HI (2013): Update on differences between childhood-onset and adult-onset systemic lupus erythematosus 2013. Arthritis Res Therapy 15: 218.
7.
Feng X, Zou Y, Pan W, et al. (2014): Associations of clinical features and prognosis with age at disease onset in patients with systemic lupus erythematosus. Lupus 23: 327-334.
8.
Amaral B, Murphy G, Ioannou Y, Isenberg DA (2014): A comparison of the outcome of adolescent and adult-onset systemic lupus erythematosus. Rheumatology; doi: 10.1093/rheumatology/ket488.
9.
Hiraki LT, Benseler SM, Tyrrell PN, et al. (2008): Clinical and laboratory characteristics and long-term outcome of pediatric systemic lupus erythematosus: a longitudinal study. J Pediatr 152: 550-556.
10.
Wierzbowska M, Gietka P, Rutkowska-Sak L (2014): Późne następstwa tocznia rumieniowatego układowego u dzieci. Reumatologia 52: 224-230.
11.
Petri M, Orbai AM, Alarcón GS, et al. (2012): Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 64: 2677-2686.
12.
Sag E, Tartaglione A, Batu ED, et al. (2014): Performance of the new SLICC classification criteria in childhood systemic lupus erythematosus: A multicentre study. Clin Exp Rheumatol 32: 440-444.
13.
Bombardier C, Gladman DD, Urowitz MM, et al. (1992): Derivation of the SLEDAI. A disease activity index for lupus patients. Arthritis Rheum 35: 630-640.
14.
Gladman D, Ginzler E, Goldsmith C, et al. (1996): The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 39: 363-369.
15.
Livingston B, Bonner A, Pope J (2012): Differences in autoantibody profiles and disease activity and damage scores between childhood – and adult-onset systemic lupus erythematosus: a meta-analysis. Semin Arthritis Rheum 42: 271-280.
16.
Weening J, D’AgatiV, Schwartz M, et al. (2004): The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int 65: 521-530.
17.
Lupus nephritis. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int 2012; Suppl 2: 221-232.
18.
Bertsias GK, Tektonidou M, Amoura Z, et al. (2012): Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis 71: 1771-1782.
19.
van Vollenhoven RF, Mosca M, Bertsias G, et al. (2014): Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis 73: 958-967.
20.
Henderson LK, Masson P, Craig JC, et al. (2013): Induction and maintenance treatment of proliferative lupus nephritis: a meta-analysis of randomized controlled trials. Am J Kidney Dis 61: 74-87.
21.
Tian SY, Feldman BM, Beyene J, et al. (2014): Immunosuppressive therapies for the induction treatment of proliferative lupus nephritis: a systematic review and network metaanalysis. J Rheumatol 4: 1998-2007.
22.
Cimaz R (2012): Pediatric rheumatic disease: Treating lupus nephritis in children – Is there a gold standard? Nat Rev Rheumatol 8: 192-193.
23.
Boumpas DT, Austin HA 3rd, Vaughn EM, et al. (1992): Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 340: 741-745.
24.
Houssiau FA, Vasconcelos C, D’Cruz D, et al. (2002): Immunosuppresive therapy in lupus nephritis (the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide). Arthritis Rheum 46: 2121-2131.
25.
Houssiau FA, Vasconcelos C, D’Cruz D, et al. (2010): The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis 69: 61-64.
26.
Illei GG, Austin HA 3rd, Crane M, et al. (2001): Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med 135: 248-257.
27.
Grootscholten C, Ligtenberg G, Hagen EC, et al. (2006): Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial. Kidney Int 70: 732-742.
28.
Arends S, Grootscholten C, Derksen RH, et al. (2012): Long-term follow-up of a randomised controlled trial of azathioprine/methylprednisolone versus cyclophosphamide in patients with proliferative lupus nephritis. Ann Rheum Dis 71: 966-973.
29.
Dooley MA, Jayne D, Ginzler EM, et al. (2011): Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med 365: 1886-1895.
30.
Appel GB, Contreras G, Dooley MA, et al. (2009): Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 20: 1103-1112.
31.
Radhakrishnan J, Moutzouris DA, Ginzler EM, et al. (2010): Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis. Kidney Int 77: 152-160.
32.
Austin HA 3rd, Illei GG, Braun MJ, et al. (2009): Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy. J Am Soc Nephrol 20: 901-911.
33.
Díaz-Lagares C, Croca S, Sangle S, et al. (2012) : Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts. Autoimmun Rev 11: 357-364.
34.
Jónsdóttir T, Gunnarsson I, Mourăo AF, et al. (2010): Clinical improvements in proliferative vs membranous lupus nephritis following B-cell depletion: pooled data from two cohorts. Rheumatology 49: 1502-1504.
35.
Rovin BH, Parikh SV (2014): Lupus nephritis: the evolving role of novel therapeutics. Am J Kidney Dis 63: 677-690.
36.
Isenberg DA, Rahman A (2014): Taking a closer look at biologic therapy for SLE. Nat Rev Rheumatol 10: 71-72.
37.
Dooley MA, Houssiau F, Aranow C, et al. (2013): Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE. Lupus 22: 63-72.
38.
Alarcón GS, McGwin G, Bertoli AM, et al. (2007): LUMINA Study Group. Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from.
39.
LUMINA, a multiethnic US cohort (LUMINA L). Ann Rheum Dis 66: 1168-1172.